US5688941A
(en)
*
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
US5681940A
(en)
*
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US20050118605A9
(en)
*
|
1996-06-06 |
2005-06-02 |
Baker Brenda F. |
Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
|
US20040171030A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
|
US20040171028A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US20040161844A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040171032A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Non-phosphorous-linked oligomeric compounds and their use in gene modulation
|
US6639062B2
(en)
|
1997-02-14 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
|
DE69834038D1
(de)
|
1997-07-01 |
2006-05-18 |
Isis Pharmaceutical Inc |
Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
|
US7321828B2
(en)
*
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
EP1080226A4
(de)
|
1998-05-21 |
2004-04-21 |
Isis Pharmaceuticals Inc |
Zusammensetzungen und methoden zur topischen verabreichung von oligonukleotiden
|
CA2329130A1
(en)
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6335439B1
(en)
|
1998-06-11 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Method of preparing phosphoramidites
|
US6743605B1
(en)
*
|
1998-06-24 |
2004-06-01 |
Enzo Life Sciences, Inc. |
Linear amplification of specific nucleic acid sequences
|
EP1105539A2
(de)
|
1998-08-21 |
2001-06-13 |
Naxcor |
Testverfahren unter verwendung von vernetzbaren immobilisierten nukleinsäuren
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6423493B1
(en)
|
1998-10-26 |
2002-07-23 |
Board Of Regents The University Of Texas System |
Combinatorial selection of oligonucleotide aptamers
|
US20060172925A1
(en)
*
|
1998-10-26 |
2006-08-03 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US20040242521A1
(en)
*
|
1999-10-25 |
2004-12-02 |
Board Of Regents, The University Of Texas System |
Thio-siRNA aptamers
|
US6492111B1
(en)
*
|
1998-11-25 |
2002-12-10 |
Isis Pharmaceuticals, Inc. |
In situ binary synthesis of biologically effective molecules
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US6147200A
(en)
*
|
1999-08-19 |
2000-11-14 |
Isis Pharmaceuticals, Inc. |
2'-O-acetamido modified monomers and oligomers
|
US6617442B1
(en)
*
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
US20030190644A1
(en)
|
1999-10-13 |
2003-10-09 |
Andreas Braun |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
EP2202241A3
(de)
*
|
2000-04-13 |
2010-07-28 |
Thomas N. Wight |
Therapeutische Verbindungen und Verfahren zur V3-Modulation, einer Versican-Isoform
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US20060166227A1
(en)
*
|
2000-06-20 |
2006-07-27 |
Stephen Kingsmore |
Protein expression profiling
|
US6323009B1
(en)
*
|
2000-06-28 |
2001-11-27 |
Molecular Staging, Inc. |
Multiply-primed amplification of nucleic acid sequences
|
US6958214B2
(en)
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
WO2002030465A2
(en)
|
2000-10-12 |
2002-04-18 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US20030072689A1
(en)
*
|
2001-08-15 |
2003-04-17 |
Third Wave Technologies, Inc. |
Polymer synthesizer
|
US7435390B2
(en)
*
|
2001-01-26 |
2008-10-14 |
Third Wave Technologies, Inc. |
Nucleic acid synthesizers
|
US6932943B1
(en)
|
2001-01-26 |
2005-08-23 |
Third Wave Technologies |
Nucleic acid synthesizers
|
US7635571B2
(en)
*
|
2000-12-07 |
2009-12-22 |
Siemens Healthcare Diagnostics Products Gmbh |
Amplified signal in binding assays
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US6573051B2
(en)
*
|
2001-03-09 |
2003-06-03 |
Molecular Staging, Inc. |
Open circle probes with intramolecular stem structures
|
ES2328796T3
(es)
|
2001-03-14 |
2009-11-18 |
Myriad Genetics, Inc. |
Interaccion tsg101-gag y uso de la misma.
|
KR100788092B1
(ko)
|
2001-06-20 |
2007-12-21 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
DE60238143D1
(de)
|
2001-09-18 |
2010-12-09 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US20030224380A1
(en)
*
|
2001-10-25 |
2003-12-04 |
The General Hospital Corporation |
Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
|
AU2002364945A1
(en)
*
|
2001-10-25 |
2003-07-09 |
Neurogenetics, Inc. |
Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
|
US20030170678A1
(en)
*
|
2001-10-25 |
2003-09-11 |
Neurogenetics, Inc. |
Genetic markers for Alzheimer's disease and methods using the same
|
US20030162190A1
(en)
*
|
2001-11-15 |
2003-08-28 |
Gorenstein David G. |
Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
US7553619B2
(en)
*
|
2002-02-08 |
2009-06-30 |
Qiagen Gmbh |
Detection method using dissociated rolling circle amplification
|
US7169916B2
(en)
*
|
2002-04-01 |
2007-01-30 |
Isis Pharmaceuticals, Inc. |
Chloral-free DCA in oligonucleotide synthesis
|
EP2011886A3
(de)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
AU2003276131A1
(en)
*
|
2002-06-18 |
2003-12-31 |
Epigenesis Pharmaceuticals, Inc. |
A dry powder oligonucleotide formulation, preparation and its uses
|
US20050287648A1
(en)
|
2002-08-05 |
2005-12-29 |
University Of Rochester |
Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
|
US7785799B2
(en)
*
|
2002-08-16 |
2010-08-31 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to flavivirus envelope protein domain III antigens
|
CA2498777C
(en)
|
2002-09-13 |
2015-01-13 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
EP2233494A3
(de)
*
|
2002-09-20 |
2013-05-29 |
Yale University |
Riboswitches, Verfahren für deren Anwendung, Zusammensetzungen damit
|
EP2272958A1
(de)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulierung von der Forkheadbox O1A-Expression
|
AU2003304278B2
(en)
*
|
2002-10-16 |
2009-03-12 |
Board Of Regents Of The University Of Texas System |
Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004041889A2
(en)
*
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
SI1569695T1
(sl)
|
2002-11-13 |
2013-08-30 |
Genzyme Corporation |
Protismiselna modulacija ekspresije apolipoproteina B
|
AU2003298650B2
(en)
|
2002-11-15 |
2010-03-11 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
WO2004046330A2
(en)
|
2002-11-15 |
2004-06-03 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
WO2004047749A2
(en)
|
2002-11-21 |
2004-06-10 |
University Of Utah Research Foundation |
Purinergic modulation of smell
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20040121338A1
(en)
*
|
2002-12-19 |
2004-06-24 |
Alsmadi Osama A. |
Real-time detection of rolling circle amplification products
|
CA2510587A1
(en)
|
2002-12-20 |
2004-07-15 |
Qiagen Gmbh |
Nucleic acid amplification
|
US9487823B2
(en)
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
EP1597366B1
(de)
|
2003-02-11 |
2012-11-21 |
Antisense Therapeutics Ltd |
Modulation der expression des insulinähnlichen wachstumsfaktor i-rezeptors
|
US7002006B2
(en)
*
|
2003-02-12 |
2006-02-21 |
Isis Pharmaceuticals, Inc. |
Protection of nucleosides
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20070141570A1
(en)
*
|
2003-03-07 |
2007-06-21 |
Sequenom, Inc. |
Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US8043834B2
(en)
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
EP1635693A2
(de)
*
|
2003-05-23 |
2006-03-22 |
Board Of Regents, The University Of Texas System |
Screening mit hohem durchsatz von aptamer-bibliotheken für die spezifische bindung an proteine auf viren und anderen erregern
|
EP1635765B1
(de)
*
|
2003-05-23 |
2013-07-17 |
Board Of Regents, The University Of Texas System |
Strukturbasiertes und kombinatorisch ausgewähltes oligonucleosid-phosphorothioat und phosphorodithioat aptamer targeting ap-1 transkriptionsfaktoren
|
WO2004108081A2
(en)
*
|
2003-06-02 |
2004-12-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
EP2241572A3
(de)
|
2003-06-03 |
2011-04-06 |
Eli Lilly And Company |
Modulation d'expression de survivine
|
ES2905724T3
(es)
|
2003-06-13 |
2022-04-11 |
Alnylam Europe Ag |
Acido ribonucleico bicatenario con elevada eficacia en un organismo
|
EP1644475A4
(de)
*
|
2003-06-20 |
2009-06-03 |
Isis Pharmaceuticals Inc |
Doppelstrang-zusammensetzungen mit einem 3'-endo-modifizierten strang zur verwendung bei der genmodulation
|
WO2005010016A2
(en)
*
|
2003-07-24 |
2005-02-03 |
Board Of Regents |
Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
CA2538252C
(en)
*
|
2003-09-18 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
EP2256201A3
(de)
|
2003-09-18 |
2012-07-04 |
Isis Pharmaceuticals, Inc. |
Modulation der eIF4E expression
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
EP2412725A3
(de)
|
2003-11-17 |
2012-04-25 |
Genentech, Inc. |
Antikörper gegen CD79b zur Behandlung von Tumoren hämatopoetischen Ursprungs
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
*
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
WO2005089268A2
(en)
|
2004-03-15 |
2005-09-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
AU2005230684B2
(en)
|
2004-04-05 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
US20050239134A1
(en)
*
|
2004-04-21 |
2005-10-27 |
Board Of Regents, The University Of Texas System |
Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
|
JP4584987B2
(ja)
|
2004-04-30 |
2010-11-24 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
C5修飾ピリミジンを含むオリゴヌクレオチド
|
CA2564251C
(en)
|
2004-05-21 |
2018-04-10 |
The Uab Research Foundation |
Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1765416A4
(de)
*
|
2004-06-03 |
2010-03-24 |
Isis Pharmaceuticals Inc |
Doppelsträngige zusammensetzungen mit unterschiedlich modifizierten strängen zur verwendung bei der genmodulation
|
WO2006023880A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
PL1809303T3
(pl)
*
|
2004-09-23 |
2019-11-29 |
Arc Medical Devices Inc |
Kompozycje farmaceutyczne i sposoby dotyczące hamowania zrostów włóknistych lub stanów zapalnych przy użyciu fukanów o niskiej zawartości siarczanów
|
NZ554277A
(en)
|
2004-10-20 |
2010-09-30 |
Antisense Therapeutics Ltd |
Antisense modulation of integrin alpha 4 expression
|
WO2006063031A2
(en)
*
|
2004-12-06 |
2006-06-15 |
Haplomics |
Allelic variants of human factor viii
|
JP2008535796A
(ja)
|
2005-03-10 |
2008-09-04 |
ジェネンテック・インコーポレーテッド |
脈管の完全性を調節するための方法及び組成物
|
US8309303B2
(en)
|
2005-04-01 |
2012-11-13 |
Qiagen Gmbh |
Reverse transcription and amplification of RNA with simultaneous degradation of DNA
|
US20060281702A1
(en)
*
|
2005-05-18 |
2006-12-14 |
Board Of Regents, The University Of Texas System |
Combinatorial selection of phosphorothioate aptamers for RNases
|
WO2007008300A2
(en)
|
2005-05-31 |
2007-01-18 |
ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
WO2006133022A2
(en)
|
2005-06-03 |
2006-12-14 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
DK2239327T3
(en)
|
2005-08-11 |
2015-05-18 |
Synthetic Genomics Inc |
A method for in vitro recombination
|
CA2617693A1
(en)
|
2005-08-17 |
2007-02-22 |
Medexis S.A. |
Composition and method for determination of ck19 expression
|
EP2338992A3
(de)
|
2005-08-29 |
2011-10-12 |
Regulus Therapeutics, Inc |
Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
|
WO2007027775A2
(en)
|
2005-08-29 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Methods for use in modulating mir-122a
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
AU2006304321B2
(en)
|
2005-10-14 |
2012-10-04 |
Musc Foundation For Research Development |
Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP1941059A4
(de)
|
2005-10-28 |
2010-11-03 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur hemmung der expression des huntingtin-gens
|
WO2007056326A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of nav1.8 gene
|
US20100069461A1
(en)
|
2005-11-09 |
2010-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
WO2007062380A2
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
US20090069263A1
(en)
*
|
2005-12-16 |
2009-03-12 |
Damha Masad J |
4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
|
JP2009524411A
(ja)
*
|
2005-12-21 |
2009-07-02 |
イェール ユニバーシティー |
リボスイッチの調節に関連した方法および組成物
|
EP1976567B1
(de)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
|
EP3210633B1
(de)
|
2006-01-26 |
2019-06-19 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und deren verwendungen in bezug auf huntingtin
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
AU2007211082B2
(en)
|
2006-01-27 |
2012-09-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
DK2314594T3
(da)
*
|
2006-01-27 |
2014-10-27 |
Isis Pharmaceuticals Inc |
6-modificerede bicykliske nukleinsyreanaloger
|
WO2007115168A2
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
WO2007125173A2
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
EP2505648A1
(de)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Verfahren zur Modulation der Expression von PTP1B
|
CA3044969A1
(en)
|
2006-05-05 |
2007-12-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gene expression
|
CA2651453C
(en)
|
2006-05-11 |
2014-10-14 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
EP2023937B1
(de)
|
2006-05-19 |
2011-10-12 |
Alnylam Pharmaceuticals Inc. |
Rnai-modulation von aha und ihre therapeutische verwendung
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
EP2023938A4
(de)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation von chrebp-expression
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
CA2660052A1
(en)
*
|
2006-08-04 |
2008-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the modulation of jnk proteins
|
US20100137440A1
(en)
*
|
2006-09-11 |
2010-06-03 |
Yale University |
Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches
|
AU2007324117B2
(en)
|
2006-10-05 |
2014-03-06 |
Massachussetts Institute Of Technology |
Multifunctional encoded particles for high-throughput analysis
|
CA2667055C
(en)
|
2006-10-18 |
2017-05-09 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
CA2670563A1
(en)
*
|
2006-11-27 |
2008-06-05 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
BRPI0720038A2
(pt)
|
2006-12-11 |
2013-12-24 |
Univ Utah Res Found |
Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US20080293053A1
(en)
*
|
2006-12-28 |
2008-11-27 |
The Regents Of The University Of Michigan |
shRNA Materials and Methods of Using Same for Inhibition of DKK-1
|
US8507200B2
(en)
|
2007-02-09 |
2013-08-13 |
Northwestern University |
Particles for detecting intracellular targets
|
US20100167290A1
(en)
*
|
2007-02-27 |
2010-07-01 |
Robert Elghanian |
Molecule attachment to nanoparticles
|
EP2471925A1
(de)
|
2007-03-22 |
2012-07-04 |
Yale University |
Verfahren und Zusammensetzungen für Riboswitches, die das alternative Spleissen kontrollieren
|
WO2008121604A2
(en)
|
2007-03-29 |
2008-10-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the ebola
|
WO2008141275A1
(en)
|
2007-05-11 |
2008-11-20 |
The Johns Hopkins University |
Biomarkers for melanoma
|
CA2687684A1
(en)
*
|
2007-05-29 |
2008-12-11 |
Yale University |
Methods and compositions related to riboswitches that control alternative splicing and rna processing
|
US20100286082A1
(en)
*
|
2007-05-29 |
2010-11-11 |
Yale University |
Riboswitches and methods and compositions for use of and with riboswitches
|
EP2170917B1
(de)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
|
WO2008151049A2
(en)
|
2007-05-30 |
2008-12-11 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
US7807372B2
(en)
*
|
2007-06-04 |
2010-10-05 |
Northwestern University |
Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
CA2692579C
(en)
*
|
2007-07-05 |
2016-05-03 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
KR101654007B1
(ko)
|
2007-08-15 |
2016-09-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
테트라하이드로피란 핵산 유사체
|
DK2682400T5
(da)
|
2007-08-28 |
2017-11-27 |
Uab Research Foundation |
Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
WO2009039466A1
(en)
|
2007-09-20 |
2009-03-26 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
WO2009060124A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
EP2245159A2
(de)
|
2007-12-10 |
2010-11-03 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und verfahren zur hemmung der expression des faktor-vii-gens
|
EP3100718B1
(de)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
EP2265627A2
(de)
*
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexitolnukleinsäureanaloga
|
WO2009111658A2
(en)
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
EP2285819B1
(de)
*
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
EP2274423A2
(de)
*
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
|
EP2982753B1
(de)
|
2008-04-18 |
2018-06-06 |
Baxter International Inc. |
Zusammensetzung auf mikrokügelchenbasis zur vorbeugung und/oder abwendung einer neuerkrankung an autoimmunem diabetes
|
EP2280995A2
(de)
*
|
2008-04-29 |
2011-02-09 |
Wyeth LLC |
Verfahren zur behandlung von entzündungen
|
EP2297322A1
(de)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation der genexpression über das abzielen kleiner endogener rna auf genpromotoren
|
WO2010014592A1
(en)
|
2008-07-29 |
2010-02-04 |
The Board Of Regents Of The University Of Texas Sytem |
Selective inhibition of polyglutamine protein expression
|
EP2334319B1
(de)
|
2008-08-25 |
2017-12-06 |
Excaliard Pharmaceuticals, Inc. |
Verfahren zur verminderten narbenbildung während der wundheilung anhand von ctgf-ausgerichteten antisense-verbindungen
|
EP3081648A1
(de)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
EP2356129B1
(de)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituierte alpha-l-bicyclische nukleoside
|
WO2010036696A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acid analogs
|
EP3109321B1
(de)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
|
US9139554B2
(en)
|
2008-10-09 |
2015-09-22 |
Tekmira Pharmaceuticals Corporation |
Amino lipids and methods for the delivery of nucleic acids
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
NO2937418T3
(de)
|
2008-10-20 |
2018-03-17 |
|
|
CA2741294C
(en)
|
2008-10-24 |
2018-04-24 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
MX2011005429A
(es)
|
2008-11-24 |
2011-06-21 |
Univ Northwestern |
Composiciones de nanoparticulas de arn polivalentes.
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
EP2370580B1
(de)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
|
RU2746478C2
(ru)
|
2008-12-04 |
2021-04-14 |
КьюРНА, Инк. |
Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
KR101546673B1
(ko)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
전자 사진용 토너 및 그의 제조방법
|
EP3243504A1
(de)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
PT2396038E
(pt)
|
2009-02-12 |
2016-02-19 |
Curna Inc |
Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
CA2754749C
(en)
|
2009-03-04 |
2019-04-30 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
ES2656290T3
(es)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
|
EP2408920B1
(de)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
|
WO2010120420A1
(en)
|
2009-04-15 |
2010-10-21 |
Northwestern University |
Delivery of oligonucleotide-functionalized nanoparticles
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
EP2421972A2
(de)
|
2009-04-24 |
2012-02-29 |
The Board of Regents of The University of Texas System |
Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
|
CA2760589C
(en)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
NZ621981A
(en)
|
2009-05-05 |
2015-09-25 |
Tekmira Pharmaceuticals Corp |
Lipid compositions
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
EP2430161A1
(de)
|
2009-05-15 |
2012-03-21 |
Yale University |
Gemm-riboswitches, strukturbasierte verbindungskonstruktion mit gemm-riboswitches sowie verfahren und zusammensetzungen zur verwendung von und mit gemm-riboswitches
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
EP2432882B1
(de)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
HUE056773T2
(hu)
|
2009-06-10 |
2022-03-28 |
Arbutus Biopharma Corp |
Továbbfejlesztett lipid készítmény
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
EP2443237B1
(de)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
|
WO2010148249A1
(en)
|
2009-06-17 |
2010-12-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
CN102597238B
(zh)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
AP3574A
(en)
|
2009-08-14 |
2016-02-08 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
US20120157324A1
(en)
|
2009-08-17 |
2012-06-21 |
Yale University |
Methylation biomarkers and methods of use
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
JP6147502B2
(ja)
|
2009-10-27 |
2017-06-14 |
スウィフト バイオサイエンシーズ, インコーポレイテッド |
ポリヌクレオチドプライマー及びプローブ
|
EP2494075B1
(de)
|
2009-10-30 |
2018-04-04 |
Northwestern University |
Templatgesteuerte nanokonjugate
|
WO2011053994A1
(en)
|
2009-11-02 |
2011-05-05 |
Alnylam Pharmaceuticals, Inc. |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
AU2010315867A1
(en)
|
2009-11-03 |
2012-06-21 |
University Of Virginia Patent Foundation |
Versatile, visible method for detecting polymeric analytes
|
CA2781469A1
(en)
|
2009-11-23 |
2011-05-26 |
Swift Biosciences, Inc. |
Devices to extend single stranded target molecules
|
CN103755809B
(zh)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー,インコーポレイテッド |
Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療
|
CA2785177C
(en)
|
2009-12-29 |
2019-09-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
CN102782134B
(zh)
|
2009-12-29 |
2017-11-24 |
库尔纳公司 |
通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2524039B1
(de)
|
2010-01-11 |
2017-11-29 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem sexualhormonbindenden globulin (shgb) mittels hemmung des natürlichen antisense-transkripts gegen shbg
|
US20120321647A1
(en)
|
2010-01-12 |
2012-12-20 |
Yale University |
Structured rna motifs and compounds and methods for their use
|
BR112012017483A2
(pt)
*
|
2010-01-14 |
2019-09-24 |
Haplomics Inc |
previsão e redução de aloimunogenicidade de terapêuticos de proteína
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
WO2011097388A1
(en)
|
2010-02-03 |
2011-08-11 |
Alnylam Pharmaceuticals, Inc. |
Selective inhibition of polyglutamine protein expression
|
WO2011097407A1
(en)
|
2010-02-04 |
2011-08-11 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
US20130101512A1
(en)
|
2010-03-12 |
2013-04-25 |
Chad A. Mirkin |
Crosslinked polynucleotide structure
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
AU2011235276B2
(en)
|
2010-03-29 |
2015-09-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病
|
WO2011133695A2
(en)
|
2010-04-20 |
2011-10-27 |
Swift Biosciences, Inc. |
Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
|
WO2011139699A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
US8993738B2
(en)
|
2010-04-28 |
2015-03-31 |
Isis Pharmaceuticals, Inc. |
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
|
BR112012027547B1
(pt)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
US20130203045A1
(en)
|
2010-05-26 |
2013-08-08 |
University Of Virginia Patent Foundation |
Method for detecting nucleic acids based on aggregate formation
|
EP2576579B1
(de)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von leberfibrose
|
WO2011156432A2
(en)
|
2010-06-07 |
2011-12-15 |
Firefly Bioworks, Inc. |
Scanning multifunctional particles
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011156713A1
(en)
|
2010-06-11 |
2011-12-15 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
US9168297B2
(en)
|
2010-06-23 |
2015-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Regulation of skin pigmentation by neuregulin-1 (NRG-1)
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
AU2011282217B2
(en)
|
2010-07-19 |
2015-12-03 |
Ionis Pharmaceuticals, Inc. |
Modulation of dystrophia myotonica-protein kinase (DMPK) expression
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
CN103210086B
(zh)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
|
EP2630241B1
(de)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
|
JP6073795B2
(ja)
|
2010-10-27 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
インターフェロン関連発生制御因子1(ifrd1)への天然アンチセンス転写物の阻害によるifrd1関連疾患の治療
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US9150926B2
(en)
|
2010-12-06 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Diagnosis and treatment of adrenocortical tumors using human microRNA-483
|
EP2649182A4
(de)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
KR101697396B1
(ko)
|
2011-02-02 |
2017-01-17 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
결합 조직 성장 인자(ctgf)를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
|
EP2670404B1
(de)
|
2011-02-02 |
2018-08-29 |
The Trustees of Princeton University |
Sirtuin-modulatoren als modulatoren der virusproduktion
|
SG192252A1
(en)
|
2011-02-03 |
2013-09-30 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
CN103459598B
(zh)
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
EP3467109A1
(de)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
MX360349B
(es)
|
2011-03-29 |
2018-10-30 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
WO2012138453A1
(en)
|
2011-04-03 |
2012-10-11 |
The General Hospital Corporation |
Efficient protein expression in vivo using modified rna (mod-rna)
|
WO2012149154A1
(en)
|
2011-04-26 |
2012-11-01 |
Swift Biosciences, Inc. |
Polynucleotide primers and probes
|
WO2012151289A2
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system to detect aggregate formation on a substrate
|
WO2012151268A1
(en)
|
2011-05-02 |
2012-11-08 |
University Of Virginia Patent Foundation |
Method and system for high throughput optical and label free detection of analytes
|
CA2838588C
(en)
|
2011-06-09 |
2021-09-14 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US9315811B2
(en)
|
2011-06-10 |
2016-04-19 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (KLKB1) expression
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
SG10201800715PA
(en)
|
2011-06-21 |
2018-02-27 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
EP2723756B1
(de)
|
2011-06-21 |
2020-03-11 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von apolipoprotein-c-iii (apoc3)-genen
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2013003808A1
(en)
|
2011-06-29 |
2013-01-03 |
Isis Pharmaceuticals, Inc. |
Methods for modulating kallikrein (klkb1) expression
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
US20150051389A1
(en)
|
2011-08-11 |
2015-02-19 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
CA2847698C
(en)
|
2011-09-14 |
2020-09-01 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
US9580713B2
(en)
|
2011-09-17 |
2017-02-28 |
Yale University |
Fluoride-responsive riboswitches, fluoride transporters, and methods of use
|
KR102102862B1
(ko)
|
2011-10-14 |
2020-04-22 |
제넨테크, 인크. |
항-HtrA1 항체 및 사용 방법
|
EP2791160B1
(de)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modifizierte mrna zusammensetzungen
|
ES2673960T3
(es)
|
2011-12-22 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Métodos para modular la expresión de un transcrito-1 de adenocarcinoma en pulmón asociado a metástasis (MALAT-1)
|
CA2860731C
(en)
|
2012-01-10 |
2023-02-28 |
M. Mahmood Hussain |
Method of treating hyperlipidemia and atherosclerosis with mir-30c
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
WO2013138536A1
(en)
|
2012-03-13 |
2013-09-19 |
Swift Biosciences, Inc. |
Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
|
KR20140136488A
(ko)
|
2012-03-15 |
2014-11-28 |
큐알엔에이, 인크. |
뇌 유래 신경영양 인자(bdnf)에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자(bdnf)관련 질환의 치료
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
US9340784B2
(en)
|
2012-03-19 |
2016-05-17 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating alpha-1-antitrypsin expression
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP2833923A4
(de)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
Modifizierte polynukleotide zur herstellung von proteinen
|
CN108949772A
(zh)
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
EP3336189A1
(de)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
WO2013177248A2
(en)
|
2012-05-22 |
2013-11-28 |
Isis Pharmaceuticals, Inc. |
Modulation of enhancer rna mediated gene expression
|
DK3461895T3
(da)
|
2012-06-25 |
2020-07-20 |
Ionis Pharmaceuticals Inc |
Modulation af ube3a-ats-ekspression
|
US20140038182A1
(en)
|
2012-07-17 |
2014-02-06 |
Dna Logix, Inc. |
Cooperative primers, probes, and applications thereof
|
US20150297629A1
(en)
|
2012-07-27 |
2015-10-22 |
Isis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
WO2014045126A2
(en)
|
2012-09-18 |
2014-03-27 |
Uti Limited Partnership |
Treatment of pain by inhibition of usp5 de-ubiquitinase
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
EP4052709A1
(de)
|
2012-10-11 |
2022-09-07 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur behandlung der kennedy-krankheit
|
AR092982A1
(es)
|
2012-10-11 |
2015-05-13 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion de receptores androgenicos
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CA3201145A1
(en)
|
2012-10-26 |
2014-05-01 |
Geron Corporation |
C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
BR112015013311A2
(pt)
|
2012-12-07 |
2017-11-14 |
Haplomics Inc |
indução de tolerancia e reparação de mutação do fator 8
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
EP2945652B1
(de)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
US9701708B2
(en)
|
2013-01-31 |
2017-07-11 |
Ionis Pharmaceuticals, Inc. |
Method of preparing oligomeric compounds using modified coupling protocols
|
AU2014216137B2
(en)
|
2013-02-14 |
2018-05-10 |
Ionis Pharmaceuticals, Inc. |
Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
CN105143470B
(zh)
|
2013-02-28 |
2020-06-09 |
德克萨斯大学系统董事会 |
用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
EP2971010B1
(de)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulierung und abgabe von modifizierten nukleosid-, nukleotid- und nukleinsäurezusammensetzungen
|
KR20230162998A
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
JP6567494B2
(ja)
|
2013-03-14 |
2019-08-28 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
4’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法
|
EP3578652B1
(de)
|
2013-03-15 |
2023-07-12 |
ModernaTX, Inc. |
Ribonukleinsäurereinigung
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3578663A1
(de)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Herstellungsverfahren zur herstellung von rna-transkripten
|
CN115261411A
(zh)
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
EP3633039A1
(de)
|
2013-05-01 |
2020-04-08 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren
|
KR102365809B1
(ko)
|
2013-05-22 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
HUE038146T2
(hu)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 IRNS készítmények és eljárások alkalmazásukra
|
US20160113911A1
(en)
|
2013-06-06 |
2016-04-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
EP3656386A1
(de)
|
2013-06-21 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils
|
EP3730614A3
(de)
|
2013-07-02 |
2020-12-30 |
Ionis Pharmaceuticals, Inc. |
Modulatoren des wachstumshormonrezeptors
|
AU2014287009B2
(en)
|
2013-07-11 |
2020-10-29 |
Modernatx, Inc. |
Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
|
AU2014292926B2
(en)
|
2013-07-25 |
2020-03-05 |
Exicure Operating Company |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
HUE048710T2
(hu)
|
2013-08-08 |
2020-08-28 |
Scripps Research Inst |
Eljárás nukleinsavak in vitro helyspecifikus enzimes jelölésére nem-természetes nukleotidok beépítésével
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
US9670492B2
(en)
|
2013-08-28 |
2017-06-06 |
Ionis Pharmaceuticals, Inc. |
Modulation of prekallikrein (PKK) expression
|
JP2016530294A
(ja)
|
2013-09-03 |
2016-09-29 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
キメラポリヌクレオチド
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
EP3043827B1
(de)
|
2013-09-13 |
2019-07-03 |
Ionis Pharmaceuticals, Inc. |
Inhibitoren des komplementfaktors b
|
WO2015051169A2
(en)
*
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
EP3052626A1
(de)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
PE20161130A1
(es)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
Composiciones y metodos para inhibir la expresion del gen alas1
|
WO2015054451A1
(en)
|
2013-10-09 |
2015-04-16 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
JP2016536303A
(ja)
|
2013-10-21 |
2016-11-24 |
ザ ジェネラル ホスピタル コーポレイション |
末梢循環腫瘍細胞クラスターおよび癌処置に関する方法
|
US9758546B2
(en)
|
2013-10-21 |
2017-09-12 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
WO2015066708A1
(en)
|
2013-11-04 |
2015-05-07 |
Northwestern University |
Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
|
CA2932122C
(en)
|
2013-12-03 |
2022-04-19 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
US10385388B2
(en)
|
2013-12-06 |
2019-08-20 |
Swift Biosciences, Inc. |
Cleavable competitor polynucleotides
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
CA2934344A1
(en)
|
2013-12-20 |
2015-06-25 |
David T. TING |
Methods and assays relating to circulating tumor cells
|
HUE052243T2
(hu)
|
2013-12-24 |
2021-04-28 |
Ionis Pharmaceuticals Inc |
Az angiopoietin-szerû 3 expressziójának modulációja
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CA2938857A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
CA2942340A1
(en)
|
2014-03-19 |
2015-09-24 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
SG10201906520RA
(en)
|
2014-04-01 |
2019-09-27 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
WO2015157555A2
(en)
|
2014-04-09 |
2015-10-15 |
The Scripps Research Institute |
Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
|
MA39835A
(fr)
|
2014-04-17 |
2017-02-22 |
Biogen Ma Inc |
Compositions et procédés de modulation de l'épissage du smn2 chez un patient
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
PE20170010A1
(es)
|
2014-05-01 |
2017-03-04 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
US10098959B2
(en)
|
2014-05-01 |
2018-10-16 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
WO2015168618A2
(en)
|
2014-05-01 |
2015-11-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
CN106255755B
(zh)
|
2014-05-01 |
2020-07-24 |
Ionis制药公司 |
用于调节血管生成素样蛋白3表达的组合物和方法
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
JP6811094B2
(ja)
|
2014-05-22 |
2021-01-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アンジオテンシノーゲン(AGT)iRNA組成物およびその使用
|
US10456445B2
(en)
|
2014-06-02 |
2019-10-29 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
TR201908550T4
(tr)
|
2014-06-04 |
2019-07-22 |
Exicure Inc |
Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
|
CN106661580B
(zh)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
用于治疗庞帕病的反义寡核苷酸
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
US10407683B2
(en)
|
2014-07-16 |
2019-09-10 |
Modernatx, Inc. |
Circular polynucleotides
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US9951327B1
(en)
|
2014-07-17 |
2018-04-24 |
Integrated Dna Technologies, Inc. |
Efficient and rapid method for assembling and cloning double-stranded DNA fragments
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
MX2017001432A
(es)
|
2014-07-31 |
2017-05-09 |
Uab Res Found |
Peptidos mimeticos de la apoe y mayor potencia para depurar el colesterol en plasma.
|
EP3183007B1
(de)
|
2014-08-19 |
2020-06-17 |
Northwestern University |
Therapeutika mit protein/oligonukleotid-kernschalennanopartikeln
|
EP3185957B1
(de)
|
2014-08-29 |
2022-06-01 |
Alnylam Pharmaceuticals, Inc. |
Patisiran zur behandlung von transthyretin-vermittelter amyloidose
|
JP2017526367A
(ja)
|
2014-08-29 |
2017-09-14 |
チルドレンズ メディカル センター コーポレーション |
癌の処置のための方法および組成物
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JP2017529082A
(ja)
|
2014-09-18 |
2017-10-05 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
ハンチントン病ハプロタイプのための対立遺伝子特異的な療法
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
EA201790771A1
(ru)
|
2014-11-10 |
2017-11-30 |
Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед |
Фармацевтические композиции длительного действия для лечения гепатита c
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
EP3218486A1
(de)
|
2014-11-10 |
2017-09-20 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Langzeitwirkende kombinationszusammensetzungen und verfahren für hepatitis c
|
CN113846101A
(zh)
|
2014-11-17 |
2021-12-28 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
CN107106493A
(zh)
|
2014-11-21 |
2017-08-29 |
西北大学 |
球形核酸纳米颗粒缀合物的序列特异性细胞摄取
|
WO2016086104A1
(en)
|
2014-11-25 |
2016-06-02 |
Ionis Pharmaceuticals, Inc. |
Modulation of ube3a-ats expression
|
CA2970795A1
(en)
|
2014-12-18 |
2016-06-23 |
Alnylam Pharmaceuticals, Inc. |
Reversir compounds
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
WO2016118812A1
(en)
|
2015-01-23 |
2016-07-28 |
Vanderbilt University |
A robust interferometer and methods of using same
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US10450342B2
(en)
|
2015-02-23 |
2019-10-22 |
Ionis Pharmaceuticals, Inc. |
Method for solution phase detritylation of oligomeric compounds
|
MX2017011010A
(es)
|
2015-02-26 |
2017-10-20 |
Ionis Pharmaceuticals Inc |
Moduladores de rodopsina p23h con especificidad de alelo.
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
BR112017020750A2
(pt)
|
2015-03-27 |
2018-06-26 |
Harvard College |
células t modificadas e métodos de produção e utilização das mesmas
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
DK3283080T3
(da)
|
2015-04-16 |
2020-04-06 |
Ionis Pharmaceuticals Inc |
Sammensætninger til modulation af c9orf72-ekspression
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
US11053495B2
(en)
|
2015-07-17 |
2021-07-06 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
WO2017021961A1
(en)
|
2015-08-04 |
2017-02-09 |
Yeda Research And Development Co. Ltd. |
Methods of screening for riboswitches and attenuators
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US11434486B2
(en)
|
2015-09-17 |
2022-09-06 |
Modernatx, Inc. |
Polynucleotides containing a morpholino linker
|
EP3353303B1
(de)
|
2015-09-25 |
2023-08-02 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
|
EP3359164A4
(de)
|
2015-10-08 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der angiotensinogenexpression
|
IL295097A
(en)
|
2015-10-30 |
2022-09-01 |
Genentech Inc |
Anti-htra1 antibodies and methods of using them
|
AU2016349954B2
(en)
|
2015-11-05 |
2022-08-25 |
Antisense Therapeutics Ltd |
Mobilizing leukemia cells
|
JP2018531605A
(ja)
|
2015-11-06 |
2018-11-01 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アポリポタンパク質(a)発現の調節
|
EP3389670A4
(de)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur behandlung von brustkrebs
|
US10993995B2
(en)
|
2015-12-07 |
2021-05-04 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
US10627396B2
(en)
|
2016-01-29 |
2020-04-21 |
Vanderbilt University |
Free-solution response function interferometry
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
WO2017223528A1
(en)
|
2016-06-24 |
2017-12-28 |
The Scripps Research Institute |
Novel nucleoside triphosphate transporter and uses thereof
|
US20190247436A1
(en)
|
2016-07-21 |
2019-08-15 |
Maxcyte, Inc. |
Methods and compositions for modifying genomic dna
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
US11364304B2
(en)
|
2016-08-25 |
2022-06-21 |
Northwestern University |
Crosslinked micellar spherical nucleic acids
|
WO2018055577A1
(en)
|
2016-09-23 |
2018-03-29 |
Synthena Ag |
Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
|
EP3522898A4
(de)
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Verfahren zum konjugieren von oligomeren verbindungen
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
EP3555292A1
(de)
|
2016-12-16 |
2019-10-23 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zur behandlung oder prävention von ttr-assoziierten krankheiten unter verwendung von transthyretin (ttr)-irna-zusammensetzungen
|
IL301053A
(en)
|
2017-01-23 |
2023-05-01 |
Regeneron Pharma |
HSD17B13 variants and their uses
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
WO2018183969A1
(en)
|
2017-03-30 |
2018-10-04 |
California Institute Of Technology |
Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
|
TWI801377B
(zh)
|
2017-04-18 |
2023-05-11 |
美商阿尼拉製藥公司 |
治療具有b型肝炎病毒(hbv)感染之個體之方法
|
US11872239B2
(en)
|
2017-04-20 |
2024-01-16 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-DNA nucleosides and uses thereof
|
WO2018193428A1
(en)
|
2017-04-20 |
2018-10-25 |
Synthena Ag |
Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
|
SG11202000167SA
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx Inc |
Incorporation of unnatural nucleotides and methods thereof
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
CA3069909A1
(en)
|
2017-07-13 |
2019-02-14 |
Northwestern University |
General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles
|
CA3071016A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of autoimmune diseases
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
KR20200089656A
(ko)
|
2017-09-19 |
2020-07-27 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
|
US11866701B2
(en)
|
2017-11-01 |
2024-01-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
EP3710587A1
(de)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 kisspeptin 1 (kiss1)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3714054A1
(de)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
|
KR20200110655A
(ko)
|
2017-12-18 |
2020-09-24 |
알닐람 파마슈티칼스 인코포레이티드 |
고이동성 그룹 박스-1 (hmgb1) irna 조성물 및 이의 사용 방법
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
MA51645A
(fr)
|
2018-01-15 |
2020-11-25 |
Ionis Pharmaceuticals Inc |
Modulateurs de l'expression de dnm2
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
AR114445A1
(es)
|
2018-02-26 |
2020-09-09 |
Synthorx Inc |
Conjugados de il-15, y sus usos
|
WO2019169219A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf4 expression
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
EP3772928A4
(de)
|
2018-04-06 |
2021-12-29 |
Children's Medical Center Corporation |
Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
|
US11365416B2
(en)
|
2018-04-11 |
2022-06-21 |
Ionis Pharmaceuticals, Inc. |
Modulators of EZH2 expression
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
PE20212131A1
(es)
|
2018-05-09 |
2021-11-05 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir de la expresion de atxn3
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
JP2021526823A
(ja)
|
2018-06-14 |
2021-10-11 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Stmn2発現を増加させるための化合物及び方法
|
AU2019294838A1
(en)
|
2018-06-27 |
2021-01-07 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing LRRK2 expression
|
US11078486B2
(en)
|
2018-07-25 |
2021-08-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
AR114551A1
(es)
|
2018-08-13 |
2020-09-16 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP3849584A4
(de)
|
2018-09-14 |
2022-06-22 |
Northwestern University |
Programmierung von proteinpolymerisation mit dna
|
AU2019344776A1
(en)
|
2018-09-18 |
2021-01-21 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
TW202028465A
(zh)
|
2018-09-28 |
2020-08-01 |
美商阿尼拉製藥公司 |
甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
MX2021005758A
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de irf5.
|
US20210332495A1
(en)
|
2018-12-06 |
2021-10-28 |
Northwestern University |
Protein Crystal Engineering Through DNA Hybridization Interactions
|
EA202191736A1
(ru)
|
2018-12-20 |
2021-10-01 |
Вир Байотекнолоджи, Инк. |
Комбинированная терапия hbv
|
CA3123617A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
CN113557023A
(zh)
|
2019-01-16 |
2021-10-26 |
建新公司 |
Serpinc1 iRNA组合物及其使用方法
|
US11214803B2
(en)
|
2019-01-31 |
2022-01-04 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
CN113728104B
(zh)
|
2019-03-29 |
2023-10-27 |
Ionis制药公司 |
用于调节ube3a-ats的化合物和方法
|
AR118513A1
(es)
|
2019-03-29 |
2021-10-20 |
Mitsubishi Tanabe Pharma Corp |
Compuestos para modular la expresión de dux4, métodos y composiciones farmacéuticas de estos
|
CN114126628A
(zh)
|
2019-05-13 |
2022-03-01 |
维尔生物科技有限公司 |
用于治疗乙型肝炎病毒(hbv)感染的组合物及方法
|
CA3138915A1
(en)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
EP3983543A4
(de)
|
2019-06-14 |
2023-05-03 |
The Scripps Research Institute |
Reagenzien und verfahren zur replikation, transkription und translation in halbsynthetischen organismen
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4013870A1
(de)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
|
WO2021030778A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
MX2022001776A
(es)
|
2019-08-15 |
2022-03-17 |
Synthorx Inc |
Terapias de combinacion de inmuno oncologia con conjugados de il-2.
|
AU2020337869A1
(en)
|
2019-08-23 |
2022-03-03 |
Synthorx, Inc. |
IL-15 conjugates and uses thereof
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
CA3150082A1
(en)
|
2019-09-10 |
2021-03-18 |
Jerod PTACIN |
IL-2 CONJUGATES AND METHODS OF USE FOR TREATING AUTOIMMUNE DISEASES
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
WO2021081026A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
JP2023500661A
(ja)
|
2019-11-01 |
2023-01-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ハンチンチン(HTT)iRNA剤組成物およびその使用方法
|
JP2022554272A
(ja)
|
2019-11-04 |
2022-12-28 |
シンソークス, インコーポレイテッド |
インターロイキン10コンジュゲートおよびその使用
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
KR20220110749A
(ko)
|
2019-11-06 |
2022-08-09 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
IL293824A
(en)
|
2019-12-13 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
US20230057461A1
(en)
|
2020-01-27 |
2023-02-23 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
WO2021167841A1
(en)
|
2020-02-18 |
2021-08-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
KR20220148230A
(ko)
|
2020-02-28 |
2022-11-04 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Smn2를 조절하기 위한 화합물 및 방법
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
CA3174725A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
EP4121534A1
(de)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
コロナウイルスiRNA組成物およびその使用方法
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CA3179411A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
MX2022012561A
(es)
|
2020-04-07 |
2022-11-07 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
MX2022013525A
(es)
|
2020-04-27 |
2023-01-24 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas.
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
JP2023524065A
(ja)
|
2020-05-01 |
2023-06-08 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Atxn1を調節するための化合物及び方法
|
JPWO2021230286A1
(de)
|
2020-05-12 |
2021-11-18 |
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150087A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
EP4150089A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4161552A1
(de)
|
2020-06-05 |
2023-04-12 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur behandlung von neoplasien
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
IL299063A
(en)
|
2020-06-18 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
|
WO2021262840A1
(en)
|
2020-06-24 |
2021-12-30 |
Vir Biotechnology, Inc. |
Engineered hepatitis b virus neutralizing antibodies and uses thereof
|
EP4171648A1
(de)
|
2020-06-25 |
2023-05-03 |
Synthorx, Inc. |
Immunonkologische kombinationstherapie mit il-2-konjugaten und anti-egfr-antikörpern
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP3978608A1
(de)
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
|
EP4225917A1
(de)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022076859A1
(en)
|
2020-10-09 |
2022-04-14 |
Synthorx, Inc. |
Immuno oncology therapies with il-2 conjugates
|
KR20230084203A
(ko)
|
2020-10-09 |
2023-06-12 |
신톡스, 인크. |
Il-2 접합체 및 펨브롤리주맙을 사용한 면역 종양 병용 요법
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022103999A1
(en)
|
2020-11-13 |
2022-05-19 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2023549563A
(ja)
|
2020-11-18 |
2023-11-27 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
アンジオテンシノーゲン発現を調節するための化合物及び方法
|
EP4256053A1
(de)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
JP2024501288A
(ja)
|
2020-12-23 |
2024-01-11 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
修飾tremの組成物及びその使用
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
WO2022147214A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022174101A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Skin cancer combination therapy with il-2 conjugates and cemiplimab
|
KR20230146048A
(ko)
|
2021-02-12 |
2023-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
|
TW202302148A
(zh)
|
2021-02-12 |
2023-01-16 |
美商欣爍克斯公司 |
使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
BR112023016645A2
(pt)
|
2021-02-26 |
2023-11-14 |
Alnylam Pharmaceuticals Inc |
Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
|
BR112023017737A2
(pt)
|
2021-03-04 |
2023-10-03 |
Alnylam Pharmaceuticals Inc |
Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022192038A1
(en)
|
2021-03-12 |
2022-09-15 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
EP4314016A1
(de)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Zyklische zellen penetrierende peptide
|
EP4314293A1
(de)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Prolindehydrogenase 2 (prodh2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
IL307926A
(en)
|
2021-04-26 |
2023-12-01 |
Alnylam Pharmaceuticals Inc |
Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
|
EP4330396A1
(de)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022235537A1
(en)
|
2021-05-03 |
2022-11-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
EP4337263A1
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TW202313117A
(zh)
|
2021-06-03 |
2023-04-01 |
美商欣爍克斯公司 |
包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
|
KR20240017911A
(ko)
|
2021-06-04 |
2024-02-08 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 해독 프레임 72(C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
BR112023026050A2
(pt)
|
2021-06-18 |
2024-03-05 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir expressão de ifnar1
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
KR20240036041A
(ko)
|
2021-07-21 |
2024-03-19 |
알닐람 파마슈티칼스 인코포레이티드 |
대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법
|
WO2023003995A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
AU2022323090A1
(en)
|
2021-08-03 |
2024-02-01 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
TW202337474A
(zh)
|
2021-08-04 |
2023-10-01 |
美商艾拉倫製藥股份有限公司 |
用於緘默血管收縮素原(AGT)的iRNA組成物及方法
|
CA3228733A1
(en)
|
2021-08-13 |
2023-02-16 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (f12) irna compositions and methods of use thereof
|
IL311139A
(en)
|
2021-09-01 |
2024-04-01 |
Entrada Therapeutics Inc |
Compounds and methods for skipping exon 44 in Duchenne muscular dystrophy
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023064530A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2022378567A1
(en)
|
2021-10-29 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|